12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Revocon 12.5
Sun Pharmaceutical (Bangladesh) Ltd.
Generic: Tetrabenazine
Safety Advices
বাংলা
English
UNSAFE
Revocon 12.5 may cause excessive drowsiness with alcohol.
CONSULT YOUR DOCTOR
Revocon 12.5 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Revocon 12.5 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
UNSAFE
Revocon 12.5 may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
CONSULT YOUR DOCTOR
There is limited information available on the use of Revocon 12.5 in patients with kidney disease. Please consult your doctor.
However, caution is advised in these patients.
UNSAFE
Revocon 12.5 is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Medicine Overview of Revocon 12.5 12.5mg Tablet
Introduction
Revocon 12.5 is a prescription medicine used to treat Huntington's disease, a condition in which nerve cells in the brain breakdown over time, thus deteriorating the person’s physical and mental abilities. It also helps to relieve uncontrollable and jerky movements of the body. Revocon 12.5 should be taken with or without food. However, it is advised to take it at the same time each day as this helps to maintain a consistent level of medicine in the body. Take this in the dose and duration as advised by your doctor and if you have missed a dose, take it as...
... Show moreUses of Revocon 12.5
- Huntington's disease
Side effects of Revocon 12.5
Common
- Nausea
- Insomnia (difficulty in sleeping)
- Anxiety
- Fatigue
- Sleepiness
- Akathisia (inability to stay still)
- Depression
How to use Revocon 12.5
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Revocon 12.5 may be taken with or without food, but it is better to take it at a fixed time.
How Revocon 12.5 works
Revocon 12.5 works by depleting the stores of certain chemical messengers in the brain that helps in controlling body movements.
Quick Tips
- You have been prescribed Revocon 12.5 to help control movement disorders such as in Huntington’s disease.
- Be cautious while driving or doing anything that requires concentration as Revocon 12.5 can cause dizziness and sleepiness.
- Inform your doctor if you experience symptoms such as high fever, sweating, muscle stiffness, and faster breathing. These may be due to a rare side effect known as the neuroleptic malignant syndrome.
- Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior.
- Do not stop taking Revocon 12.5 without talking to your doctor first as it may cause worsening of symptoms.
Brief Description
Indication
Movement disorders, Moderate to severe tardive dyskinesia
Administration
May be taken with or without food.
Adult Dose
Oral Huntington Disease Indicated for treatment of chorea associated with Huntington’s disease Adult: Individualize and slowly titrate dosage over several weeks to identify a dose that reduces chorea and is well tolerated Total daily dose up to 50 mg/day 12.5 mg PO qDay initially; after 1 week, the dose should be increased to 12.5 mg q12hr Maintenance: Titrate slowly by weekly intervals of 12.5 mg/day to identify dose that reduces chorea and is tolerated If daily dose is 37.5 to 50 mg/day, administer in divided doses q8hr Elderly: Initially 12.5 mg daily, increased gradually. Total Daily dose >50 mg/day If...
... Show moreChild Dose
Safety and efficacy not established
Contraindication
Hypersensitivity. Lactation. Hepatic impairment. Patients who are actively suicidal, or who have untreated or inadequately treated depression.
Mode of Action
Reversibly inhibits human vesicular monoamine transporter type 2 (VMAT2), resulting in decreased uptake of monoamines (eg, dopamine, serotonin, norepinephrine, histamine) into synaptic vesicles and depletion of monoamine stores from nerve terminals
This effect is similar to reserpine, but with less peripheral activity and is shorter-acting
Precaution
May exacerbate symptoms of parkinsonism. Caution to be exercised when driving or performing skilled tasks. Pregnancy. Increased risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Monitor for emergence or worsening of depression, suicidality, or unusual changes in behavior. Caution in patients with a history of depression or prior suicide attempts or ideation.
Side Effect
>10%
Sedation/somnolence (31%),Fatigue (22%),Insomnia (22%),Depression (19%),Akathisia (19%),Extrapyramidal event (15%),Anxiety (15%),Nausea (13%)
1-10%
Irritability (9%),Bruising (6%),Vomiting (6%),Decreased appetite (4%),Dysuria (4%),Obsessive reaction (4%),Imbalance (9%),Parkinsonism/bradykinesia (9%),Dizziness (4%),Dysarthria (4%),Unsteady gait (4%),Headache (4%)
Frequency Not Defined
QTc prolongation,Neuroleptic malignant syndrome,Orthostatic Hypotension,Restlessness and agitation,Dysphagia,Depression and suicidality
Potentially Fatal: Neuroleptic malignant syndrome (NMS).
Pregnancy Category Note
Pregnancy
There are no adequate data on the developmental risk associated with therapy in pregnant women; administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality
Lactation
There are no data on presence of tetrabenazine or metabolites in human milk, effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and potential adverse effects on breastfed infant or underlying maternal condition
Interaction
Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
